← back to search

Uwe Platzbecker

University College London · DE
Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Hematopoietic Stem Cell Transplantation, and Chronic Myeloid Leukemia Treatments.
h-index
88
citations
38,815
works
1,511
NIH funding
primary concept
Medicine
email

Recent publications

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT
Blood 2025cited by 16position: middledoi
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
Journal of Clinical Oncology 2025cited by 13position: middledoi
Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohort
Blood Advances 2025cited by 11position: middledoi
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial
Journal of Clinical Oncology 2025cited by 10position: firstdoi
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Blood 2025cited by 9position: middledoi
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial
Blood 2025cited by 9position: middledoi
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST
Blood 2025cited by 8position: middledoi
Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia
Nature Communications 2025cited by 6position: middledoi
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies
npj Digital Medicine 2025cited by 6position: middledoi
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma
Cancer Cell 2025cited by 6position: middledoi
Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
HemaSphere 2025cited by 5position: middledoi
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients
Blood Cancer Journal 2025cited by 5position: middledoi
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
Leukemia 2025cited by 4position: middledoi
Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells
Blood 2025cited by 3position: middledoi
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
Blood 2025cited by 3position: middledoi
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working Party
Bone Marrow Transplantation 2025cited by 3position: middledoi
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Archives of Pathology & Laboratory Medicine 2025cited by 2position: middledoi
American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Blood Advances 2025cited by 2position: middledoi
Preclinical Efficacy of Tasquinimod in Myelodysplastic Neoplasms: Restoring Erythropoiesis and Mitigating Bone Loss
HemaSphere 2025cited by 1position: middledoi
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology 2024cited by 78position: middledoi
Molecular taxonomy of myelodysplastic syndromes and its clinical implications
Blood 2024cited by 63position: middledoi
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
npj Digital Medicine 2024cited by 56position: middledoi
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
The Lancet Haematology 2024cited by 49position: middledoi
Molecular and clinical presentation of <i>UBA1</i>-mutated myelodysplastic syndromes
Blood 2024cited by 44position: middledoi
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Journal of Clinical Oncology 2024cited by 37position: middledoi
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
Blood 2024cited by 34position: middledoi
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche
Leukemia 2024cited by 31position: lastdoi
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
Blood 2024cited by 28position: middledoi
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
The Lancet Haematology 2024cited by 27position: middledoi
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations
Blood 2024cited by 23position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Martin Bornhäuser · German Cancer Research Center33 papers (2012–2025)Christoph Röllig · Hopp Children's Cancer Center Heidelberg23 papers (2012–2025)Christian Thiede · TiGenix (Spain)22 papers (2012–2025)Johannes Schetelig · Center for Systems Biology Dresden21 papers (2012–2025)Gerhard Ehninger · TU Dresden21 papers (2012–2022)Aristoteles Giagounidis · Marien Hospital Düsseldorf19 papers (2013–2024)Michael Krämer · Mercer University18 papers (2012–2022)Pierre Fenaux · Hôpital Nord18 papers (2013–2024)Mikkael A. Sekeres · Yale University17 papers (2014–2025)Hubert Serve · Goethe University Frankfurt16 papers (2012–2025)Nicolaus Kröger · Universität Ulm15 papers (2013–2025)Richard F. Schlenk · Institute of Human Genetics15 papers (2012–2024)Valeria Santini · University Hospital Leipzig14 papers (2018–2025)Sabine Käyser · University of Mannheim14 papers (2016–2024)Guillermo Garcia‐Manero · Cancer Clinic14 papers (2016–2024)Katja Sockel · German Cancer Society14 papers (2012–2025)Jan Moritz Middeke · Digital Health Cooperative Research Centre13 papers (2013–2025)Friedrich Stölzel · Nationales Centrum für Tumorerkrankungen Dresden13 papers (2013–2023)Ulrich Germing · Bristol-Myers Squibb (Switzerland)12 papers (2012–2022)Carsten Müller‐Tidow · Heidelberg University12 papers (2017–2025)